Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20580230 | 1.00 | BCAT2 (0.49) | BCAT2AOC3KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL22444835 | 0.84 | HDAC4 (0.43) | KDM4E | |
| SCHEMBL26087473 | 0.84 | HDAC4 (0.43) | KDM4E | |
| SCHEMBL20580382 | 0.84 | HDAC4 (0.43) | KDM4E | |
| SCHEMBL18921533 | 0.81 | RIPK1 (0.50) | BCAT2SMN1; SMN2NPC1RAB9ARIPK1 | |
| SCHEMBL22456387 | 0.81 | RIPK1 (0.50) | BCAT2SMN1; SMN2NPC1RAB9ARIPK1 | |
| SCHEMBL21783573 | 0.81 | RIPK1 (0.50) | BCAT2AOC3SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22232743 | 0.81 | RIPK1 (0.50) | BCAT2SMN1; SMN2NPC1RAB9ARIPK1 | |
| SCHEMBL29433920 | 0.80 | PNMT (0.56) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL20580058 | 0.80 | GAA (0.42) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | US | disclosed |
| WO-2024106914-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI INC. (KR) | 2024-05-23 | — | — | WO | disclosed |
| EP-4342895-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-03-27 | — | — | EP | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2023187471-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023068881-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | 주식회사 보로노이바이오 | 2023-04-27 | — | — | WO | disclosed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | BCAT2 1444/4885AOC3 3839/4885KDM4E 3677/4885 |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | BCAT2 4405/4885AOC3 4489/4885KDM4E 4151/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | BCAT2 4405/4885AOC3 4489/4885KDM4E 4151/4885 |
| US-20240166640-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | BCAT2 1444/4885AOC3 3839/4885KDM4E 3677/4885 |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | BCAT2 1444/4885AOC3 3839/4885KDM4E 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.